Compare · DYN vs RGNX

DYN vs RGNX

Side-by-side comparison of Dyne Therapeutics Inc. (DYN) and REGENXBIO Inc. (RGNX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. DYN focuses on Biotechnology: Pharmaceutical Preparations, while RGNX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
  • DYN is the larger of the two at $3.00B, about 6.3x RGNX ($478.7M).
  • DYN has been more active in the news (12 items in the past 4 weeks vs 10 for RGNX).
  • Both have 24 recent analyst ratings on file.
MetricDYNRGNX
Company
Dyne Therapeutics Inc.
REGENXBIO Inc.
Price
-
-
Market cap
$3.00B
$478.7M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2020
2015
News (4w)
12
10
Recent ratings
24
24
DYN

Dyne Therapeutics Inc.

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.

RGNX

REGENXBIO Inc.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Latest DYN

Latest RGNX